Nimodipinum [Inn-Latin] en es it fr

Nimodipinum [Inn-Latin] Brand names, Nimodipinum [Inn-Latin] Analogs

Nimodipinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Nimodipinum [Inn-Latin] Chemical_Formula


Nimodipinum [Inn-Latin] RX_link

Nimodipinum [Inn-Latin] fda sheet

Nimodipinum_[Inn-Latin] FDA

Nimodipinum [Inn-Latin] msds (material safety sheet)

Nimodipinum [Inn-Latin] Synthesis Reference

No information avaliable

Nimodipinum [Inn-Latin] Molecular Weight

418.44 g/mol

Nimodipinum [Inn-Latin] Melting Point

No information avaliable

Nimodipinum [Inn-Latin] H2O Solubility

No information avaliable

Nimodipinum [Inn-Latin] State


Nimodipinum [Inn-Latin] LogP


Nimodipinum [Inn-Latin] Dosage Forms


Nimodipinum [Inn-Latin] Indication

For the treatment of subarachnoid bleeding.

Nimodipinum [Inn-Latin] Pharmacology

Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.

Nimodipinum [Inn-Latin] Absorption

No information avaliable

Nimodipinum [Inn-Latin] side effects and Toxicity

No information avaliable

Nimodipinum [Inn-Latin] Patient Information

No information avaliable

Nimodipinum [Inn-Latin] Organisms Affected

Humans and other mammals